- Home
- STLA vs ONC Comparison
STLA vs ONC Comparison
Compare STLA & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STLA
- ONC
- Stock Information
- Founded
- STLA 2021
- ONC 2010
- Country
- STLA Netherlands
- ONC Switzerland
- Employees
- STLA N/A
- ONC N/A
- Industry
- STLA Auto Manufacturing
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- STLA Consumer Discretionary
- ONC Health Care
- Exchange
- STLA Nasdaq
- ONC Nasdaq
- Market Cap
- STLA 31.6B
- ONC 34.8B
- IPO Year
- STLA N/A
- ONC N/A
- Fundamental
- Price
- STLA $10.11
- ONC $330.91
- Analyst Decision
- STLA Buy
- ONC Strong Buy
- Analyst Count
- STLA 4
- ONC 12
- Target Price
- STLA $12.65
- ONC $362.08
- AVG Volume (30 Days)
- STLA 16.0M
- ONC 287.3K
- Earning Date
- STLA 07-29-2025
- ONC 11-06-2025
- Dividend Yield
- STLA 5.85%
- ONC N/A
- EPS Growth
- STLA N/A
- ONC N/A
- EPS
- STLA N/A
- ONC 0.29
- Revenue
- STLA $171,605,402,237.00
- ONC $4,998,489,124.00
- Revenue This Year
- STLA N/A
- ONC N/A
- Revenue Next Year
- STLA $5.19
- ONC N/A
- P/E Ratio
- STLA N/A
- ONC $1,166.02
- Revenue Growth
- STLA N/A
- ONC 53.47
- 52 Week Low
- STLA $8.39
- ONC $170.99
- 52 Week High
- STLA $14.28
- ONC $385.22
- Technical
- Relative Strength Index (RSI)
- STLA 49.02
- ONC 45.33
- Support Level
- STLA $9.22
- ONC $363.02
- Resistance Level
- STLA $9.84
- ONC $364.97
- Average True Range (ATR)
- STLA 0.28
- ONC 16.77
- MACD
- STLA -0.08
- ONC -0.93
- Stochastic Oscillator
- STLA 53.29
- ONC 27.33
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.